Cullinan Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Cullinan reported Q2 2026 net loss of $53.7M (vs. $70.1M in Q2 2025) on R&D expenses of $44.4M (vs. $61.0M). Cash position: $356.0M as of June 30, 2026, providing runway into 2029. Key near-term catalysts: CLN-978 multi-dose data in RA (Q3 2026) and SLE (Q4 2026); velinotamig multi-dose SLE data (Q4 2026); CLN-049 Phase 2 initiation in R/R AML (Q3 2026) following positive FDA End-of-Phase 1 meeting. Zipalertinib (EGFR ex20ins) NDA with FDA, PDUFA date February 27, 2027; Cullinan eligible for $30M and up to $100M upon 2L and 1L approvals, plus 50/50 profit share in U.S.
Why this rating
Strong cash runway into 2029 (80% of current market cap) and multiple near-term clinical readouts de-risk pipeline. However, company remains pre-commercial; upside dependent on clinical trial success, not yet materialized.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.